We studied 97 patients with residual NFMAs to identify factors affecting tumor control such as the time of RT and tumor immunopathology. Partial pituitary surgery was performed either by trans frontal (35 patients) or transsphenoidal (62 patients) approach. High voltage RT (mean total dose 50.5 Gy) was given to 41/97 patients. Twenty out of 41 patients had RT within the first year after surgery (Group A) and 21/41 had RT after 1year (Group B). Fifty six out of 97 patients with surgery, without RT, represent the control group (Group C) (Fig 
SUBJECTS AND METHODS
We studied 97 patients with residual NFMAs to identify factors affecting tumor control such as the time of RT and tumor immunopathology. 
RESULTS INTRODUCTION
The high voltage radiotherapy (RT) after surgery for nonfunctioning pituitary macro adenomas (NFMAs) is still controversial, subjected to rapid technical and medical progress.
AIM
To appreciate the best period of time for RT in patients with pituitary macro adenomas with residual tumor after surgery.
CONCLUSIONS
It is tempting to suggest as an optimal time for radiotherapy is the first year post partial surgery of nonfunctioning pituitary macro adenomas. Special attention should be given for uni/plurihormonal silent adenomas (as shown by immunohistochemistry). In the control group C, without RT, the patients with silent hormone adenomas have a regrowth rate more frequently than patients with null cell adenomas (p=0.060, CI 90%), (Table 2) . In the groups A and B, we observed by contrast that postoperative RT is associated with lower risk of residual tumor regrowth for these type of tumors expressing hormones vs null cell adenomas (OR = 0.16) (Fig 2) . It is important to emphasize that patients from group A vs patients from group control, without RT, have had more tumors with cavernous sinus invasion (p = 0.038), with high postoperative remnant (p = 0.001 ) or with size more than 2 cm (p = 0.001 ) and with residual mass outside the sella (p = 0.003). Patients from group B vs control, group C, showed also statistically significant higher postoperative remnant (p=0.047) and residual mass with suprasellar extension (p=0.023), (Table 1 ).
*p < 0.05 vs patients with RT Table 2 . The rate of the residual tumor regrowth in relation to the high voltage radiotherapy (RT)
